Restricted mobility of specific functional groups reduces anti-cancer drug activity in healthy cells
Research output: Contribution to journal › Journal article › peer-review
Standard
Restricted mobility of specific functional groups reduces anti-cancer drug activity in healthy cells. / Longo Martins, Murillo; Ignazzi, Rosanna; Eckert, Juergen; Watts, Benjamin; Kaneno, Ramon; Zambuzzi, Willian F; Daemen, Luke; Saeki, Margarida J; Bordallo, Heloisa N.
In: Scientific Reports, Vol. 6, 22478, 2016.Research output: Contribution to journal › Journal article › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Restricted mobility of specific functional groups reduces anti-cancer drug activity in healthy cells
AU - Longo Martins, Murillo
AU - Ignazzi, Rosanna
AU - Eckert, Juergen
AU - Watts, Benjamin
AU - Kaneno, Ramon
AU - Zambuzzi, Willian F
AU - Daemen, Luke
AU - Saeki, Margarida J
AU - Bordallo, Heloisa N
PY - 2016
Y1 - 2016
N2 - The most common cancer treatments currently available are radio- and chemo-therapy. These therapies have, however, drawbacks, such as, the reduction in quality of life and the low efficiency of radiotherapy in cases of multiple metastases. To lessen these effects, we have encapsulated an anti-cancer drug into a biocompatible matrix. In-vitro assays indicate that this bio-nanocomposite is able to interact and cause morphological changes in cancer cells. Meanwhile, no alterations were observed in monocytes and fibroblasts, indicating that this system might carry the drug in living organisms with reduced clearance rate and toxicity. X-rays and neutrons were used to investigate the carrier structure, as well as to assess the drug mobility within the bio-nanocomposite. From these unique data we show that partial mobility restriction of active groups of the drug molecule suggests why this carrier design is potentially safer to healthy cells.
AB - The most common cancer treatments currently available are radio- and chemo-therapy. These therapies have, however, drawbacks, such as, the reduction in quality of life and the low efficiency of radiotherapy in cases of multiple metastases. To lessen these effects, we have encapsulated an anti-cancer drug into a biocompatible matrix. In-vitro assays indicate that this bio-nanocomposite is able to interact and cause morphological changes in cancer cells. Meanwhile, no alterations were observed in monocytes and fibroblasts, indicating that this system might carry the drug in living organisms with reduced clearance rate and toxicity. X-rays and neutrons were used to investigate the carrier structure, as well as to assess the drug mobility within the bio-nanocomposite. From these unique data we show that partial mobility restriction of active groups of the drug molecule suggests why this carrier design is potentially safer to healthy cells.
U2 - 10.1038/srep22478
DO - 10.1038/srep22478
M3 - Journal article
C2 - 26932808
VL - 6
JO - Scientific Reports
JF - Scientific Reports
SN - 2045-2322
M1 - 22478
ER -
ID: 160795942